SiRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.

ABSTRACT: There is an urgent need for new therapies that can halt or reverse the course of chronic kidney disease with minimal side-effect burden on the patient. Small interfering RNA (siRNA) nanoparticles are new therapeutic entities in clinical development that could be useful for chronic kidney disease treatment because they combine the tissue-specific targeting properties of nanoparticles with the gene-specific silencing effects of siRNA. Recent reports have emerged demonstrating that the kidney, specifically the glomerulus, is a readily accessible site for nanoparticle targeting. Here, we explore the hypothesis that intravenously administered polycationic cyclodextrin nanoparticles containing siRNA (siRNA/CDP-NPs) can be used for delivery of siRNA to the glomerular mesangium. We demonstrate tha

SUBMITTER: Zuckerman JE 

PROVIDER: S-EPMC4376487 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature